TherapeuticsMD (TXMD) Receivables - Other (2012 - 2026)

TherapeuticsMD (TXMD) has reported Receivables - Other for 8 consecutive years, with $3.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables - Other fell 9.32% year-over-year to $3.4 million; the trailing twelve-month figure through Jun 2026 stood at $3.4 million (down 9.32% YoY), and the FY2025 full-year result was $3.5 million, down 1.04% from the prior year.
• Receivables - Other rose to $3.4 million in Q2 2026 per TXMD's latest filing, from $3.2 million in the prior quarter.
• Across five years, Receivables - Other topped out at $3.7 million in Q2 2025 and bottomed at $2.9 million in Q2 2024.
• Historically, Receivables - Other has averaged $3.3 million across 4 years, with a median of $3.3 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Receivables - Other climbed 28.71% in 2025, then declined 9.32% in 2026.
• Over 4 years, Receivables - Other stood at $3.1 million in 2023, then grew by 15.28% to $3.6 million in 2024, then slipped by 1.04% to $3.5 million in 2025, then fell by 3.72% to $3.4 million in 2026.
• According to Business Quant data, Receivables - Other over the past three periods registered $3.4 million, $3.2 million, and $3.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.